The treatment of chronic lymphocytic leukemia (CLL) has significantly shifted from chemoimmunotherapy to targeted therapies like Bruton's tyrosine kinase and BCL2 inhibitors. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.